Revolution Medicines, Inc.

RVMDW

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001628171

SEC filings (opens in a new tab)

In the last 90 days, Revolution Medicines, Inc. insiders filed 0 open-market purchases and 19 sales; 22 institutions reported holding it in 13F filings for Q2 2026, worth $93.0M in total; no superinvestor holds it.

Other share classesRVMD

Key figures

Market capClose on Nov 10, 2026: $41.8B
Insider buysOpen market, last 90 days: 0
Insider sellsLast 90 days, $78.4M in total: 19
13F holdersQ2 2026, −1 vs. previous quarter: 22
13F valueReported value at the end of Q2 2026: $93.0M
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $0; No comparable prior period
Net income, FY2025: -$1.13B; No comparable prior period
Free cash flow, FY2025: -$913.7M; No comparable prior period
Revenue, Q3 FY2026: $197.6M; No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 1.33K; Shares sold short
Change: −251; −15.9% vs. previous
Days to cover: 1.00; At average daily volume

Superinvestors holding RVMDW, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding RVMDW at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Revolution Medicines, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Oct 28, 2026 (view filing)6:00 PM ET	Oct 26	2 days	Mancini AnthonySee Remarks	SSale	−2.31K	$186.99	−$431.9K	−5.5%39.8K after	10b5-1
Oct 1, 2026 (view filing)6:00 PM ET	Sep 29	2 days	Sandler Alan B.Chief Development Officer	SSale	−6.31K	$202.14	−$1.28M	−10.7%52.6K after	5 lots10b5-1
Sep 29, 2026 (view filing)6:00 PM ET	Sep 25	4 days	Cislini JeffSVP & General Counsel	SSale	−765	$207.32	−$158.6K	−1.5%51.8K after	10b5-1
Sep 28, 2026 (view filing)6:00 PM ET	Sep 24-25	4 days	Mancini AnthonySee Remarks	SSale	−3.71K	$200.45	−$743.3K	−8.5%39.8K after	2 lots10b5-1
Sep 24, 2026 (view filing)6:00 PM ET	Sep 22	2 days	Anderson Elizabeth MDirector	SSale	−10.1K	$193.04	−$1.96M	−70.1%4.33K after	5 lots10b5-1
Sep 22, 2026 (view filing)6:00 PM ET	Sep 18	4 days	Mancini AnthonySee Remarks	SSale	−1.76K	$196.94	−$347.4K	−4.2%40.4K after	10b5-1
Sep 18, 2026 (view filing)6:06 PM ET	Sep 16	2 days	Sandler Alan B.Chief Development Officer	SSale	−341	$199.24	−$67.9K	−0.6%52.9K after	2 lots10b5-1
Sep 18, 2026 (view filing)6:05 PM ET	Sep 16	2 days	Mancini AnthonySee Remarks	SSale	−1.77K	$199.24	−$353.4K	−4.0%42.1K after	2 lots10b5-1
Sep 18, 2026 (view filing)6:04 PM ET	Sep 16	2 days	Kelsey Stephen MichaelSee Remarks	SSale	−5.57K	$199.24	−$1.11M	−1.9%286.3K after	2 lots10b5-1
Sep 18, 2026 (view filing)6:03 PM ET	Sep 16	2 days	Horn Margaret AChief Operating Officer	SSale	−4.97K	$199.24	−$989.6K	−3.2%149.7K after	2 lots10b5-1

Top 10 13F holders, Q2 2026

See all 22 holders

The largest institutional positions in Revolution Medicines, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding RVMDW in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
LMR Partners LLP	5,066,598	$47.5M	0.35%	+1,228,574+32.0%	Added
D. E. Shaw & Co., Inc.	1,580,345	$14.9M	0.01%	00.0%	Unchanged
Sculptor Capital LP	709,670	$6.66M	0.07%	−249,152−26.0%	Reduced
Price T Rowe Associates Inc	579,550	$5.45M	0.00%	00.0%	Unchanged
Caption Management, LLC	517,685	$4.86M	0.17%	00.0%	Unchanged
Adage Capital Partners GP, L.L.C.	500,000	$4.69M	0.01%	00.0%	Unchanged
Perceptive Advisors LLC	250,000	$2.34M	0.04%	00.0%	Unchanged
Bleichroeder LP	200,000	$1.88M	0.34%	00.0%	Unchanged
Wolverine Asset Management LLC	154,544	$1.45M	0.02%	−16,154−9.5%	Reduced
Farallon Capital Management, L.L.C.	120,085	$1.13M	0.01%	00.0%	Unchanged